PeterH.SayreMD

Professor, Diabetes Center, UCSF School of Medicine

Dr. Sayre is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
400 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-353-2421

Fax+1 415-353-2467

University of California (San Diego) Medical CenterResidency, Internal Medicine, 1990 - 1993
Rutgers Robert Wood Johnson Medical SchoolClass of 1990

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

725 citations
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta
Science Translational Medicine. 2015-11-25
48 citations
Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients
Vadim Jucaud, Abraham Shaked, Michele DesMarais, Peter H. Sayre, Sandy Feng
Hepatology. 2019-03-01
90 citations
Outcomes of immunosuppression minimization and withdrawal early after liver transplantation
Abraham Shaked, Michele DesMarais, H. Kopetskie, Sandy Feng, Jeffrey D. Punch
American Journal of Transplantation. 2019-05-01

Journal Articles

Prevalence and Impact of De Novo DSA During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients
Sandy Feng, Josh Levitsky, Peter Sayre, Matthew J Everly, Abraham Shaked, Hepatology

Abstracts/Posters

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Peter H. Sayre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019